Basic Information

Gene symbol STAT3 Synonyms ADMIO, ADMIO1, APRF, HIES Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description signal transducer and activator of transcription 3

GTO ID GTC1858
Trial ID NCT03421353
Disease Advanced Solid Tumor
Altered gene STAT3
Therapeutic/Target gene Target gene
TherapyASO
Treatment ISIS-STAT3rx|AZD9150|ISIS 481464|IONIS-STAT3-2.5Rx
Co-treatment Durvalumab
PhasePhase1
Recruitment statusActive, Not Recruiting
TitleA Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and Subsequently in Patients With Non-Small-Cell Lung Cancer
Year2018
CountryUnited States
Company sponsorAstraZeneca
Other ID(s)D5660C00016|REFMAL 558|264476|2017-004925-34
Vector information
VectorNo vector was used

Clinical Result

Cohort1: AZD9150_Q2W_Durvalumab
Administration route intravenous infusion
Dosage AZD9150, every two weeks (Q2W)|Durvalumab, every four weeks (Q4W)
Age Adult, Older_Adult
Cohort2: AZD9150_QW_Durvalumab_Cisplatin_5-Flourouracil
Administration route intravenous infusion
Dosage AZD9150, weekly (QW)|Durvalumab, every three weeks (Q3W)|Cisplatin, on Day 1|5-Flourouracil, over Days 1 to 4 every three weeks for up to 18 weeks
Age Adult, Older_Adult
Cohort3: AZD9150_Q2W_Durvalumab_Cisplatin_5-Flourouracil
Administration route intravenous infusion
Dosage AZD9150, every two weeks (Q2W)|Durvalumab, every three weeks (Q3W)|Cisplatin, on Day 1|5-Flourouracil, over Days 1 to 4 every three weeks for up to 18 weeks
Age Adult, Older_Adult
Cohort4: AZD9150_Durvalumab_Cisplatin_Carboplatin_Gemcitabine
Administration route intravenous infusion
Dosage AZD9150, every two weeks (Q2W)|Durvalumab, every three weeks (Q3W)|Cisplatin, on Day 1|Carboplatin, on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks|Gemcitabine, on Days 1 and 8 for up to 18 weeks
Age Adult, Older_Adult
Cohort5: AZD9150_Durvalumab_Carboplatin_Nab-paclitaxel
Administration route intravenous infusion
Dosage AZD9150, every two weeks (Q2W)|Durvalumab, every three weeks (Q3W)|Carboplatin, on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks|Nab-paclitaxel, on Days 1, 8, and 15 for up to 18 weeks
Age Adult, Older_Adult
Cohort6: AZD9150_Durvalumab_Intravenous infusion
Administration route intravenous infusion
Dosage AZD9150, weekly (QW)|durvalumab, 1500 mg, every four weeks (Q4W)
Age Adult, Older_Adult
Cohort7: AZD9150_Durvalumab_Subcutaneous Injection
Administration route subcutaneous injection
Dosage AZD9150, weekly (QW)|durvalumab, 1500 mg, every four weeks (Q4W)
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph